Fosaprepitant

Generic name
Fosaprepitant
Brand name
ATC Code
A04AD12
Compare …

Fosaprepitant

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Prophylaxis for nausea and vomiting in chemotherapy for one-day or multi-day schedules
  • Intravenous
    • 6 months up to 18 years and ≥ 6 kg
      • Initial dose: Day 1: 3 mg/kg/dose, once only. Max: 115 mg/day.
      • Maintenance dose: Days 2 and 3: 2 mg/kg/day in 1 dose. Max: 80 mg/day.
        • run in over 30 minutes for children aged > 12 years and 60 minutes for children aged < 12.
Prophylaxis for nausea and vomiting in chemotherapy: ALTERNATIVE for one-day schedules
  • Intravenous
    • 6 months up to 2 years and ≥ 6 kg
      • 5 mg/kg/dose, once only. Max: 150 mg/dose.
        • combined with a 5-HT3 antagonist plus a corticosteroid if required.
        • Run in over 60 minutes.
    • 2 years up to 12 years
      • 4 mg/kg/dose, once only. Max: 150 mg/dose.
        • combined with a 5-HT3 antagonist plus a corticosteroid if required.
        • Run in over 60 minutes.
    • ≥ 12 years
      • 150 mg/dose, once only.
        • combined with a 5-HT3 antagonist plus a corticosteroid if required.
        • Run in over 30 minutes.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIEMETICS AND ANTINAUSEANTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Serotonin (5HT3) antagonists
A04AA02
A04AA01
A04AA05
Other antiemetics
A04AD12
A04AD01

Reference

  1. Merck, Sharpe & Dohme BV, SmPC Ivemend (Eu/1/07/437/003) 30-07-2018, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose